Spring Bank to Host Conference Call to Discuss Fourth Quarter and Fiscal Year 2018 Results on Monday, March 11
Conference Call to be Held at 8:00am Eastern Time
HOPKINTON, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that it will host a conference call to discuss its results for the fourth quarter and fiscal year ended December 31, 2018 and its 2019 development outlook at 8:00am Eastern Time on Monday, March 11, 2019.
| Conference Call Details | |
| Date: | March 11, 2019 |
| Time: | 8:00am Eastern Time |
| US: | 877-407-0789 |
| International: | 201-689-8562 |
| Conference ID: | 13687792 |
| Webcast: | |
A replay of the call may be accessed by visiting Spring Bank’s website.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleotide platform. The company designs its compounds to target and modulate the activity of specific proteins implicated in various disease states. The company’s lead product candidate, inarigivir, is being developed for the treatment of chronic hepatitis B virus (HBV). Inarigivir is designed to selectively activate within infected cells retinoic acid-inducible gene 1 (RIG-I), which has been shown to inhibit HBV viral replication and induce the intracellular interferon signaling pathways for antiviral defense. The company is also developing its lead STING agonist product candidate, SB 11285, an immunotherapeutic agent for the treatment of selected cancers.
CONTACTS
Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
(508) 473-5993
LifeSci Advisors, LLC
Ashley R. Robinson
(617) 535-7742
Source: Spring Bank Pharmaceuticals
